Navigation Links
Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference
Date:1/10/2014

n general, these patients are severely ill and have a great medical need for a topical therapy that may better manage their symptoms.  In the second quarter of 2014, Rigel will initiate a Phase 2 study of R348 in patients with dry eye as a result of primary GvHD.

R118, AMPK Activator for Intermittent Claudication
Intermittent claudication (IC) refers to the muscle pain associated with peripheral artery disease (PAD) caused by either atherosclerosis or inflammation.  Patients with IC have difficulty with simple activities, like walking, and current therapies do not provide sufficient relief.  IC affects more than 5% of the population age 65 or older, but anyone with PAD may also suffer the effects of IC.   Preclinical evaluation of R118, an AMPK activator, has shown it to be a central regulator of lipid and metabolic activity and capable of increasing muscle endurance.  Rigel plans to initiate a Phase 1 trial of R118 in patients with IC in the first half of 2014.

Partnerships
In addition to the five clinical programs noted above, Rigel also has products in varying stages of preclinical and clinical development with three pharmaceutical partners.  

In June 2012, Rigel and AstraZeneca announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor as a potential treatment for asthma.  AstraZeneca is responsible for the development of R256.  It's continued efforts to bring R256 into first-in-human studies triggered the $5.75 million milestone payment to Rigel.

Partners BerGenBio and Daiichi Sankyo are developing Rigel's Axl Kinase inhibitor and a Ubiquitin Ligase inhibitor, respectively, for their potential safety and efficacy in treating various cancers.  Both of these molecules are currently in Phase 1 clinical development.

Financial Update
Rigel ended 2013 with approxim
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel to Present at Oppenheimer Healthcare Conference
2. Rigel Announces Third Quarter 2013 Financial Results
3. Rigel Provides Pipeline Update
4. Rigel to Present at Stifel Healthcare Conference
5. Rigel To Focus On ITP, DLE And Dry Eye
6. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
7. Rigel Announces Second Quarter 2013 Financial Results
8. Rigel Will Resume Responsibility for Fostamatinib Program
9. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
10. Rigel Announces First Quarter 2013 Financial Results
11. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... N.C. , Oct. 24, 2014 ... provide Medical Affairs leaders with a forum for ... The consortium has developed a mechanism for creating ... where leaders discuss key findings from the Medical ... has completed the analysis for the first roundtable ...
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)... Investor-Edge has initiated coverage on the following ... Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), Threshold ... Inc. (NASDAQ: IDRA ), and Merrimack Pharmaceuticals ... can be accessed at: http://investor-edge.com/register . ... at 4,419.48, up 2.40%, the Dow Jones Industrial Average ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
(Date:10/25/2014)... October 25, 2014 Triton Algae ... today announced Dr. Xun Wang has joined ... & Development. , Triton has developed a patented synthetic ... proteins. According to Dr. Wang, the platform uses algae ... systems. He says, “Algae are unique because they can ...
(Date:10/25/2014)... October 25, 2014 More than 50 ... Circle Reception on Monday at the home of Jim ... hear from guest speaker Dr. Winifred Lender on finding ... Dr. Lender, a Santa Barbara psychologist, author and Noozhawk ... benefits of living in the digital age. Our digital ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets ... affordable prices. Bob Seger & The Silver Bullet Band ... Arena are going on sale October 25 and are ... to browse the selection of tickets for Bob Seger ... famous singer is touring North America beginning next month, ...
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Current osteoporosis screening guidelines ... women at risk for osteoporosis-related fractures, a new ... fractures, we need tools that help us accurately ... that we can target these at-risk people for ... of medicine in the division of general internal ...
Breaking Medicine News(10 mins):Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... grow a lot in 13,years, and a successful ... diagnostic sleep testing and sleep apnea treatment, is ... moving into new corporate,offices. Recently named one ... America, SleepQuest has moved its headquarters from Redwood,City ...
... Center in Portland Finds BSGI Capable of Significantly ... Changing Clinical Management in Patients, NEWPORT ... significantly changed patient management at one breast,center in Portland, Oregon. ... reported that although still fairly new to,BSGI, the procedure has ...
... Study finds men with more than 3 kids are more ... A young, trim farmer with four or more children: According to ... to reach 100 years of age. , The research, based largely ... off excess weight in youth, farming and fathering a large number ...
... therapeutic human drugs using modified mushrooms may help mount ... to plant pathologists who have received a federal grant ... of plant pathology at Penn State and holder of ... "We are looking to address several public health issues ...
... data today at the 60th Annual Meeting of ... that doing the right kind of brain exercise can ... , Dr. Elizabeth Zelinski of the University of Southern ... study (Improvement in Memory with Plasticity-based Adaptive Cognitive Training) ...
... LOS ANGELES, Calif., Nov. 19 ,Natrol, Inc, (Nasdaq: ... of,nationally branded nutritional products, and Gener8Xion Entertainment, Inc.,(OTC ... have executed a letter of intent for a ... Division. Natrol intends to,exclusively license the "Living Pure" ...
Cached Medicine News:Health News:SleepQuest Continues Growth, Moves Headquarters 2Health News:Breast-Specific Gamma Imaging (BSGI) Changes Patient Care Management 2Health News:Farming, Fatherhood Hallmarks of Men Who Live to 100 2Health News:Farming, Fatherhood Hallmarks of Men Who Live to 100 3Health News:Farming, Fatherhood Hallmarks of Men Who Live to 100 4Health News:Mushrooms may aid rapid vaccine response 2Health News:New research on aging and cognitive training presented at GSA's Annual Meeting 2Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 2Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 3Health News:Natrol, Inc. (Nasdaq: NTOL) and Gener8Xion Entertainment (BB: GNXE) Announce Strategic Alliance to Create a New Health and Wellness Division 4
0.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
1 x 2 teeth and 5.5 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm....
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish....
Medicine Products: